Is Neoadjuvancy with Imatinib Useful Before Mohs Surgery in Locally Advanced Dermatofibrosarcoma Protuberans? Experience of a Dermato-Oncology Referral Center
International Journal of Molecular Sciences · 01.04.2026 · 27 (7) · 3204
DOI: 10.3390/ijms27073204 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 01.04.2026. Verfasst von A Bota-Llorca und 11 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral School, Catholic University of Valencia San Vicente Mártir, 46001 Valencia, Spain. Hauptthemen laut MEDLINE: Imatinib Mesylate, Dermatofibrosarcoma, Mohs Surgery, Skin Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad Católica de Valencia San Vicente Mártir.
Abstract (Originalsprache)
Dermatofibrosarcoma protuberans (DFSP) is a rare cutaneous sarcoma in which complete surgical excision is standard treatment, although some tumors are initially unresectable. Neoadjuvant imatinib has been proposed in these cases, but data on its histopathological and molecular effects and long-term outcomes remain limited. To evaluate the clinical, histopathological and molecular impacts of neoadjuvant imatinib prior to modified Mohs surgery (MMS) in locally advanced DFSP. Single-center, retrospective study. After a mean of 10 months of neoadjuvant imatinib, partial tumor size reduction was observed in 60% of patients (mean reduction 37.8%), while the remaining cases showed disease stabilization; no complete responses were recorded. All tumors exhibited marked volumetric and consistency reduction, with histology revealing extensive hypocellular hyaline regression and attenuated CD34 and nestin expression. Persistence of COL1A1–PDGFB fusion transcripts was detected in post-treatment samples. Following MMS, local recurrence occurred in 30% of patients at long-term after a mean of 10.8-year follow-up since the last surgery. Neoadjuvant imatinib in locally advanced DFSP results in tumor volume reduction without decreasing the final surgical defect. The histological response is typically patchy and may compromise detection of residual disease, potentially increasing the risk of local recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Doctoral School, Catholic University of Valencia San Vicente Mártir, 46001 Valencia, Spain.
- Dermatology Department, Fundación Instituto Valenciano de Oncología, 46009 Valencia, Spain.
- Laboratory of Molecular Biology, Fundación Instituto Valenciano de Oncología, 46009 Valencia, Spain.
- Pathology Department, Fundación Instituto Valenciano de Oncología, 46009 Valencia, Spain.
ORCID-Profile: B Llombart-Cussac, C Serra-Guillén, J A López-Guerrero, E Nagore, F Mayo, O Sanmartín
Förderung
- Universidad Católica de Valencia San Vicente Mártir
Zitieren
APA
Bota-Llorca, A., Llombart-Cussac, B., Serra-Guillén, C., López-Guerrero, J. A., Traves, V., Sanmartín-Martínez, J. J., Requena, C., Nagore, E., Padilla-Esquivel, J., Millán-Esteban, D., Mayo, F., & Sanmartín, O. (2026). Is Neoadjuvancy with Imatinib Useful Before Mohs Surgery in Locally Advanced Dermatofibrosarcoma Protuberans? Experience of a Dermato-Oncology Referral Center. International Journal of Molecular Sciences, 27(7), 3204. https://doi.org/10.3390/ijms27073204
Vancouver
Bota-Llorca A, Llombart-Cussac B, Serra-Guillén C, López-Guerrero JA, Traves V, Sanmartín-Martínez JJ, et al. Is Neoadjuvancy with Imatinib Useful Before Mohs Surgery in Locally Advanced Dermatofibrosarcoma Protuberans? Experience of a Dermato-Oncology Referral Center. International Journal of Molecular Sciences. 2026;27(7):3204. doi:10.3390/ijms27073204
BibTeX
@article{BotaLlorca2026,
author = {Bota-Llorca, A and Llombart-Cussac, B and Serra-Guillén, C and López-Guerrero, J A and Traves, V and Sanmartín-Martínez, J J and Requena, C and Nagore, E and Padilla-Esquivel, J and Millán-Esteban, D and Mayo, F and Sanmartín, O},
title = {Is Neoadjuvancy with Imatinib Useful Before Mohs Surgery in Locally Advanced Dermatofibrosarcoma Protuberans? Experience of a Dermato-Oncology Referral Center},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {7},
pages = {3204},
doi = {10.3390/ijms27073204}
}
EUVIMED